Back to Search
Start Over
Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study
- Source :
- Critical Care, Vol 23, Iss 1, Pp 1-13 (2019), Critical Care, Critical Care, BioMed Central, 2019, 23 (1), pp.371. ⟨10.1186/s13054-019-2649-5⟩
- Publication Year :
- 2019
- Publisher :
- BMC, 2019.
-
Abstract
- Background There is little descriptive data on Stenotrophomonas maltophilia hospital-acquired pneumonia (HAP) in critically ill patients. The optimal modalities of antimicrobial therapy remain to be determined. Our objective was to describe the epidemiology and prognostic factors associated with S. maltophilia pneumonia, focusing on antimicrobial therapy. Methods This nationwide retrospective study included all patients admitted to 25 French mixed intensive care units between 2012 and 2017 with hospital-acquired S. maltophilia HAP during intensive care unit stay. Primary endpoint was time to in-hospital death. Secondary endpoints included microbiologic effectiveness and antimicrobial therapeutic modalities such as delay to appropriate antimicrobial treatment, mono versus combination therapy, and duration of antimicrobial therapy. Results Of the 282 patients included, 84% were intubated at S. maltophilia HAP diagnosis for duration of 11 [5–18] days. The Simplified Acute Physiology Score II was 47 [36–63], and the in-hospital mortality was 49.7%. Underlying chronic pulmonary comorbidities were present in 14.1% of cases. Empirical antimicrobial therapy was considered effective on S. maltophilia according to susceptibility patterns in only 30% of cases. Delay to appropriate antimicrobial treatment had, however, no significant impact on the primary endpoint. Survival analysis did not show any benefit from combination antimicrobial therapy (HR = 1.27, 95%CI [0.88; 1.83], p = 0.20) or prolonged antimicrobial therapy for more than 7 days (HR = 1.06, 95%CI [0.6; 1.86], p = 0.84). No differences were noted in in-hospital death irrespective of an appropriate and timely empiric antimicrobial therapy between mono- versus polymicrobial S. maltophilia HAP (p = 0.273). The duration of ventilation prior to S. maltophilia HAP diagnosis and ICU length of stay were shorter in patients with monomicrobial S. maltophilia HAP (p = 0.031 and p = 0.034 respectively). Conclusions S. maltophilia HAP occurred in severe, long-stay intensive care patients who mainly required prolonged invasive ventilation. Empirical antimicrobial therapy was barely effective while antimicrobial treatment modalities had no significant impact on hospital survival. Trial registration clinicaltrials.gov, NCT03506191
- Subjects :
- Male
[SDV]Life Sciences [q-bio]
Stenotrophomonas maltophilia
Critical Care and Intensive Care Medicine
Hospital-acquired pneumonia
law.invention
Antimicrobial therapy
0302 clinical medicine
Anti-Infective Agents
law
030212 general & internal medicine
Hospital Mortality
ComputingMilieux_MISCELLANEOUS
0303 health sciences
biology
lcsh:Medical emergencies. Critical care. Intensive care. First aid
Middle Aged
Antimicrobial
Intensive care unit
3. Good health
Intensive Care Units
Treatment Outcome
Female
medicine.medical_specialty
Combination therapy
03 medical and health sciences
Internal medicine
Intensive care
medicine
Pneumonia, Bacterial
Humans
Aged
Retrospective Studies
030306 microbiology
business.industry
Research
Healthcare-Associated Pneumonia
Retrospective cohort study
lcsh:RC86-88.9
medicine.disease
biology.organism_classification
Pneumonia
business
Gram-Negative Bacterial Infections
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Follow-Up Studies
Subjects
Details
- Language :
- English
- ISSN :
- 13648535 and 1466609X
- Volume :
- 23
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Critical Care
- Accession number :
- edsair.doi.dedup.....038150a304b15ebfb36529d05f8185ce